Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Anthony

Showing results (741-750 of 785) with videos related to

Pageof 79
Sort By:
Science Translational Medicine|September 7, 2022
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infectionKevin O Saunders, Robert J Edwards, Kedamawit Tilahun, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Cell Reports|December 28, 2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal ModelsKevin O Saunders, Laurent K Verkoczy, Chuancang Jiang, et al.
Nature Biotechnology|January 9, 2018
Functional interrogation and mining of natively paired human V<sub>H</sub>:V<sub>L</sub> antibody repertoiresBo Wang, Brandon J DeKosky, Morgan R Timm, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
The Journal of Experimental Medicine|October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Journal of Virology|July 29, 2011
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori, Kwan-Ki Hwang, Xi Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Antiviral Research|April 17, 2023
Longitudinal analyses using <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster modelsYu Cong, Ji Hyun Lee, Donna L Perry, et al.
Pageof 79

Showing results (741-750 of 785) with videos related to

Sort By:
Pageof 79
Science Translational Medicine|September 7, 2022
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infectionKevin O Saunders, Robert J Edwards, Kedamawit Tilahun, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Cell Reports|December 28, 2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal ModelsKevin O Saunders, Laurent K Verkoczy, Chuancang Jiang, et al.
Nature Biotechnology|January 9, 2018
Functional interrogation and mining of natively paired human V<sub>H</sub>:V<sub>L</sub> antibody repertoiresBo Wang, Brandon J DeKosky, Morgan R Timm, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
The Journal of Experimental Medicine|October 12, 2011
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua-Xin Liao, Xi Chen, Supriya Munshaw, et al.
Journal of Virology|July 29, 2011
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori, Kwan-Ki Hwang, Xi Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Antiviral Research|April 17, 2023
Longitudinal analyses using <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster modelsYu Cong, Ji Hyun Lee, Donna L Perry, et al.
Pageof 79